Albert Empedrad, MD
Endocrinology, Diabetes & Metabolism · Hamilton, NJNPI 1699899914
Payments from drug & device makers
Across 237 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$710
- AstraZeneca$676
- Novo Nordisk$435
- Lilly USA, LLC$434
- Boehringer Ingelheim$293
- Abbott$267
- plus $864 from 19 others
What the payments were for
- Food & beverage$3,668100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 52 | $710 |
| AstraZeneca(2 entities) | 32 | $676 |
| Novo Nordisk | 35 | $435 |
| Lilly USA, LLC | 32 | $434 |
| Boehringer Ingelheim | 20 | $293 |
| Abbott | 13 | $267 |
| Amneal Pharmaceuticals LLC | 12 | $187 |
| Merck | 8 | $109 |
| Bayer | 4 | $79 |
| Xeris Pharmaceuticals, Inc. | 5 | $75 |
| Corcept Therapeutics | 5 | $74 |
| Medtronic(2 entities) | 2 | $58 |
| Insulet Corporation | 3 | $51 |
| Dexcom, Inc. | 2 | $34 |
| Amgen | 2 | $30 |
| Ascensia Diabetes Care US Inc. | 1 | $27 |
| Halozyme Inc | 1 | $23 |
| AbbVie | 1 | $19 |
| Valeritas, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Zealand Pharma US, Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Ascendis Pharma Endocrinology Inc | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
How this compares
$3,679 in reported general payments places this provider in the 60th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 424 | $577,516 |
| MounjaroTirzepatide | 253 | $339,842 |
| JardianceEmpagliflozin | 128 | $165,762 |
| JanuviaSitagliptin Phosphate | 146 | $156,408 |
| TrulicityDulaglutide | 119 | $151,280 |
| Tresiba Flextouch U-100Insulin Degludec | 118 | $96,179 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $75,338 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 142 | $66,648 |
| FarxigaDapagliflozin Propanediol | 71 | $61,328 |
| TradjentaLinagliptin | 64 | $58,593 |
| Teriparatide | 14 | $56,508 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 92 | $45,687 |
| RybelsusSemaglutide | 34 | $40,067 |
| Humalog Kwikpen U-100Insulin Lispro | 135 | $38,653 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 254 | $26,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $435 | $622,399480 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $434 | $504,823410 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy | $293 | $247,440222 claims |
| MerckJanuvia, Janumet, Janumet Xr, Steglatro | $109 | $201,505211 claims |
| AstraZenecaFarxiga | $676 | $61,32871 claims |
| Antares Pharma, Inc.Xyosted | $14 | $15,75116 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $710 | $12,49813 claims |
| AbbVieSynthroid | $19 | $9,847101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Hamilton
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Sunil AsnaniBrick$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.